What is this blog about?
This is a timestamped, best-ideas, long-only biotech and life sciences research publication focused on generating meaningful alpha within your sector allocation. I prioritize quality over quantity, which means publishing cadence will vary.
Paid subscribers can access My Watchlist here, and prospective subscribers can review the periodically updated performance archive here. Reported performance is indicative and will vary as allocations and position sizes evolve.
Investment Philosophy:
Biotech: These are active trading vehicles designed to be held as a diversified basket to mitigate idiosyncratic risk. At times, however, optimal positioning may warrant concentration in a select few names where conviction and asymmetry are highest.
Life Science/Medtech: These are intended as longer-term holdings given their compounding characteristics. Positioning here is typically more concentrated by design, reflecting structural durability and multi-year underwriting.
Actionability: Each post is actionable upon publication — the equity is within a defined “buy range” at the time of the timestamp. This structure ensures accountability. That said, this is not a trading journal. Paid subscribers receive all articles, access to the private chat, and direct messaging. Conviction Tier is reserved for select members who want monthly portfolio updates and deeper insight into my positioning and personal process.
Exits: Each biotech pick includes a Price Target (PT) representing my estimate of fair value. While I do not issue formal sell alerts, the PT serves as a framework for when I intend to begin scaling out. These PTs may be updated periodically.
Thank you again for joining and subscribing to this community.
Join the crew
Why join 1,700+ biotech professionals? Back of the Napkin Bios isn’t just a newsletter; it’s a signalling research tool used by buyside analysts and investors to find an edge. My readers have seen significant returns and rely on my proximity and insight to navigate complex biopharma markets.
‘You got great in-depth analysis on bio.’ — athi (Paid Subscriber)
To learn more about the tech platform that powers this publication, visit Substack.com.
